{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:39:29Z","timestamp":1790203169281,"version":"4.1.0"},"reference-count":92,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,29]],"date-time":"2019-12-29T00:00:00Z","timestamp":1577577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography\/computed tomography (PET\/CT). PET\/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET\/CT with different radiopharmaceuticals in the clinical practice of MM.<\/jats:p>","DOI":"10.3390\/molecules25010134","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T05:49:41Z","timestamp":1577684981000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[{"name":"Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-9472","authenticated-orcid":false,"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,29]]},"reference":[{"key":"ref_1","unstructured":"Altekruse, S.F., Kosary, C.L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., and Cho, H. (2019, December 05). SEER Cancer Statistics Review, 1975\u20132007, Available online: http:\/\/seer.cancer.gov\/csr\/1975_2007\/index.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: New diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00259-016-3576-1","article-title":"Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting","volume":"44","author":"Glaudemans","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review","volume":"118","author":"Regelink","year":"2012","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: A systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/RLU.0000000000000773","article-title":"(18)F-FDG dynamic PET\/CT in patients with multiple myeloma: Patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate","volume":"40","author":"Sachpekidis","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_14","first-page":"469","article-title":"Comparison of (18)F-FDG PET\/CT and PET\/MRI in patients with multiple myeloma","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.3324\/haematol.2018.213041","article-title":"Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography\/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma","volume":"104","author":"Sachpekidis","year":"2019","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): Experience with 77 patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/1078-0432.CCR-18-0741","article-title":"Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of \u0394SUVmax in the FDG-Avid Patients of the IMAJEM Study","volume":"24","author":"Bailly","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/RLU.0b013e3181b06bc5","article-title":"Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET","volume":"34","author":"Hoffmann","year":"2009","journal-title":"Clin. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0609.2010.01575.x","article-title":"Combining FDG-PET\/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma","volume":"86","author":"Elliott","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-40320-5_7","article-title":"Multiple Myeloma Minimal Residual Disease","volume":"Volume 169","author":"Roccaro","year":"2016","journal-title":"Plasma Cell Dyscrasias. Cancer Treatment and Research"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2967\/jnumed.118.217539","article-title":"Hexokinase-2 expression in MET-positive FDG-negative multiple myeloma","volume":"60","author":"Kircher","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): Final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00259-006-0183-6","article-title":"Incidental finding of an 11C-choline PET positive solitary plasmacytoma lesion","volume":"33","author":"Ambrosini","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/ CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: A pilot study","volume":"43","author":"Balogova","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_38","first-page":"167","article-title":"Is fluorine-18-fluorocholine PET\/CT suitable for the detection of skeletal involvement of multiple myeloma?","volume":"21","author":"Meckova","year":"2018","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_39","first-page":"33","article-title":"The clinical use of PET with (11)C-acetate","volume":"2","author":"Grassi","year":"2012","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ymben.2009.02.001","article-title":"Metabolic characterization of a hyper-productive state in an antibody producing NS0 myeloma cell line","volume":"11","author":"Khoo","year":"2009","journal-title":"Metab. Eng."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12149-009-0325-6","article-title":"Incidental finding of an 11C-acetate PET-positive multiple myeloma","volume":"24","author":"Lee","year":"2010","journal-title":"Ann. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-Acetate PET\/CT for metabolic characterization of multiple myeloma: A comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-013-2520-x","article-title":"(11)C-Acetate as a new biomarker for PET\/CT in patients with multiple myeloma: Initial staging and postinduction response assessment","volume":"41","author":"Lin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","article-title":"Value of 11C-methionine PET in imaging brain tumours and metastases","volume":"40","author":"Glaudemans","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.121.2.409","article-title":"Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma","volume":"121","author":"Hammerton","year":"1978","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1148\/radiol.2422051980","article-title":"Multiple Myeloma: Molecular Imaging with C-Methionine PET\/CT\u2014Initial Experience","volume":"242","author":"Dankerl","year":"2007","journal-title":"Radiology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-012-2333-3","article-title":"Clinical value of 11C-methionine PET\/CT in patients with plasma cell malignancy: Comparison with 18F-FDG PET\/CT","volume":"40","author":"Nakamoto","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4\u2032-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.14696","article-title":"[11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions","volume":"181","author":"Lapa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/RLU.0000000000002638","article-title":"Comparison of 11C-Choline and 11C-Methionine PET\/CT in Multiple Myeloma","volume":"44","author":"Lapa","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nanni, C., Fanti, S., and Zanoni, L. (2019). PET\/CT with Standard Non-FDG Tracers in Multiple Myeloma. Molecular Imaging in Multiple Myeloma, Springer.","DOI":"10.1007\/978-3-030-19019-4"},{"key":"ref_54","first-page":"95","article-title":"Applications of PET imaging with the proliferation marker [18F]-FLT","volume":"59","author":"Peck","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2967\/jnumed.116.178434","article-title":"Repeatability of 18F-FLT PET in a multicenter study of patients with high-grade glioma","volume":"58","author":"Lodge","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/RLU.0b013e31820aa1a1","article-title":"F-18 FLT PET: A noninvasive diagnostic tool for visualization of the bone marrow compartment in patients with aplastic anemia: A pilot study","volume":"36","author":"Agool","year":"2011","journal-title":"Clin. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-018-0383-7","article-title":"Assessment of glucose metabolism and cellular proliferation in multiple myeloma: A first report on combined 18F-FDG and 18F-FLT PET\/CT imaging","volume":"8","author":"Sachpekidis","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)\u2013dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: A symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies","volume":"1","author":"Liu","year":"2017","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fendo.2018.00313","article-title":"Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis","volume":"9","author":"Coniglio","year":"2018","journal-title":"Front Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In Vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Herrmann","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma-Comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pan, Q., Cao, X., Luo, Y., Li, J., Feng, J., and Li, F. (2019). Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: Comparison to 18F-FDG PET\/CT. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-019-04605-z"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.2967\/jnumed.110.077933","article-title":"Molecular mechanisms of bone 18F-NaF deposition","volume":"51","author":"Czernin","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2967\/jnumed.110.082263","article-title":"SNM. SNM practice guideline for sodium 18F-fluoride PET\/CT bone scans 1.0","volume":"51","author":"Segall","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-015-3138-y","article-title":"(18)F-NaF PET\/CT: EANM procedure guidelines for bone imaging","volume":"42","author":"Beheshti","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.114.150391","article-title":"18F-fluoride PET used for treatment monitoring of systemic cancer therapy: Results from the National Oncologic PET Registry","volume":"56","author":"Hillner","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_75","first-page":"633","article-title":"Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET","volume":"33","author":"Hawkins","year":"1992","journal-title":"J. Nucl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18 F-fluoride: Applying new technology to an old tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2967\/jnumed.111.100883","article-title":"The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology","volume":"53","author":"Kurdziel","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12149-012-0647-7","article-title":"Role of 18F-fluoride PET\/CT in the assessment of multiple myeloma: Initial experience","volume":"27","author":"Nishiyama","year":"2013","journal-title":"Ann. Nucl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1097\/RLU.0000000000000285","article-title":"Different lesions revealed by 18F-FDG PET\/CT and 18F-NaF PET\/CT in patients with multiple myeloma","volume":"39","author":"Xu","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/RLU.0000000000000908","article-title":"18F-FDG and 18F-NaF PET\/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement","volume":"40","author":"Oral","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-014-2721-y","article-title":"PET\/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: Comparison of distribution patterns and tracers\u2019 pharmacokinetics","volume":"41","author":"Sachpekidis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00277-015-2410-3","article-title":"Is there any complimentary role of F-18 NaF PET\/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET\/CT and F-18 FDG NaF PET\/CT","volume":"94","author":"Ak","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_83","first-page":"148","article-title":"Quantitative analysis of 18F-NaF dynamic PET\/CT cannot differentiate malignant from benign lesions in multiple myeloma","volume":"7","author":"Sachpekidis","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"44","author":"Sachpekidis","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2007.07.002","article-title":"18F-Fluoride positron emission tomography and positron emission tomography\/computed tomography","volume":"37","author":"Mishani","year":"2007","journal-title":"Semin. Nucl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00117-013-2629-8","article-title":"PET-CT in der nuklearmedizinischen Diagnostik des multiplen Myeloms [PET-CT for nuclear medicine diagnostics of multiple myeloma]","volume":"54","year":"2014","journal-title":"Radiologe"},{"key":"ref_87","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/RLU.0000000000000629","article-title":"18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: Is this hypoxia-driven?","volume":"40","author":"Slart","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_92","first-page":"203","article-title":"Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma","volume":"60","author":"Ulaner","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/1\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:46:32Z","timestamp":1760190392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/1\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,29]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["molecules25010134"],"URL":"https:\/\/doi.org\/10.3390\/molecules25010134","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,29]]}}}